Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 9/20 | 0.65 |
| ▸ | CDK2 | P24941 | 9/20 | 0.65 |
| ▸ | CCNK | O75909 | 4/20 | 0.58 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.58 |
| ▸ | CDC7 | O00311 | 3/20 | 0.48 |
| ▸ | PIM1 | P11309 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | CLK2 | P49760 | 2/20 | 0.48 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | PRKX | P51817 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719570 | 0.91 | CCNK (0.71) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL2724281 | 0.75 | CCNK (0.62) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL10325990 | 0.74 | CCNK (0.58) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL20839635 | 0.74 | CCNK (1.00) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL30009427 | 0.74 | CCNK (1.00) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL27959619 | 0.73 | PTGDR2 (0.43) | CCNE1CDK2CCNKCDK12CDC7 | |
| SCHEMBL27818284 | 0.73 | NR1I3 (0.50) | CCNKCDK12CDC7PIM1GSK3B | |
| SCHEMBL858766 | 0.72 | CAMKK2 (0.64) | CDK2CDC7PIM1GSK3BDAPK3 | |
| SCHEMBL20849889 | 0.72 | CCNK (0.79) | CCNE1CDK2CCNKCDK12DAPK3 | |
| SCHEMBL20849907 | 0.71 | CCNK (1.00) | CCNE1CDK2CCNKCDK12KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | claimed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | claimed |
| CN-102414211-B | 3- ([1,2,3] triazol-4-yl) pyrrolo [2,3-b ] pyridine derivatives | MERCK PATENT GMBH | 2014-06-04 | — | — | CN | disclosed |
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2427461-A1 | 3-(Ý1,2,3¨TRIAZOLE-4-YL)-PYRROLOÝ2,3-B¨PYRIDINE DERIVATES | Merck Patent GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | PDK1, PDK2, PDK3 | CCNE1 135/4885CDK2 12/4885CCNK 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.